Mesoblast (AU: MSB)

Last close As at 17/07/2024

0.93

0.23 (32.86%)

Market capitalisation

605m

Edison Investment Research is terminating coverage on Mesoblast. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | edison tv

Mesoblast: Edison Open House Healthcare 2022

Healthcare | Update

Mesoblast — A significant impact on back pain

Healthcare | edison tv

Mesoblast – Edison Open House interview

Healthcare | Update

Mesoblast — Novartis licenses ARDS program

Sector

Healthcare

Balance Sheet

Forecast net cash (US$m)

16.5

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 36.8 (12.3) (53.5)
Relative 27.6 (7.6) (50.0)
52 week high/low A$2.0/A$0.6

Financials

Edison Investment Research is terminating coverage on Mesoblast. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2020A 31.6 (64.8) (79.6) (13.28) N/A N/A
2021A 7.4 (89.3) (104.3) (17.09) N/A N/A
2022E 8.6 (83.2) (92.6) (14.29) N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

Update

Healthcare

Mesoblast — Novartis licenses ARDS program

Update

Healthcare

Mesoblast — An important next several months

Update

Healthcare

Mesoblast — Moving closer to key catalysts

Outlook

Healthcare

Mesoblast — Increasingly positive on aGvHD

Update

Healthcare

Mesoblast — Waiting for readouts

Update

Healthcare

Mesoblast — Confident management

Update

Healthcare

Mesoblast — Funding to deliver key data in 2017

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free